S&P: CVS unaffected

Standard & Poor's said CVS Caremark Corp.'s (BBB+/negative/A-2) announcement that it reached agreements with the U.S. Drug Enforcement Administration and the U.S. Attorneys' Offices for the Central District of California and District of Nevada will not affect its ratings or outlook.

The settlement regards allegations that, in 2007 and 2008, some CVS/pharmacy stores in California and Nevada engaged in unlawful sales of pseudoephedrine. CVS agreed to pay the government $75 million in civil penalties and $2.6 million in profit forfeitures. The agency said this incident has a limited impact on the company's credit profile because of its strong cash flow generation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.